Orthofix Medical Inc OFIX.OQ OFIX.O is expected to show a fall in quarterly revenue when it reports results on August 5 for the period ending June 30 2025
The Lewisville Texas-based company is expected to report a 0.9% decrease in revenue to $196.89 million from $198.62 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Orthofix Medical Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Orthofix Medical Inc is $23.00, about 52% above its last closing price of $11.04
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.26 | -0.40 | -0.08 | Beat | 79.8 |
Dec. 31 2025 | -0.07 | -0.05 | 0.02 | Beat | 140 |
Sep. 30 2024 | -0.12 | -0.15 | 0.07 | Beat | 146.7 |
Jun. 30 2024 | -0.21 | -0.19 | 0.05 | Beat | 125.9 |
Mar. 31 2024 | -0.34 | -0.33 | -0.13 | Beat | 61 |
Dec. 31 2023 | -0.07 | -0.08 | 0.02 | Beat | 126.2 |
Sep. 30 2023 | -0.21 | -0.21 | 0.07 | Beat | 133.5 |
Jun. 30 2023 | -0.45 | -0.47 | 0.02 | Beat | 104.2 |
This summary was machine generated August 1 at 14:38 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)